Abstract:In this work we disclose a new family of biscyclometallated Ir( III ) complexes of the general formula [Ir(C^N) 2 (N^N)]Cl ( IrL1–IrL5 ), where HC^N is 1-phenyl-β-carboline and N^N ligands ( L1–L5 ) are different diimine ligands that differ from each other in the number of aromatic rings fused to the bipyridine scaffold. The photophysical properties of IrL1–IrL5 were thoroughly studied, and theoretical calculations were performed for a deeper comprehension of the respective variations along the series. All complexes exhibited high photostability under blue light irradiation. An increase in the number of aromatic rings led to a reduction in the HOMO–LUMO band gap causing a red-shift in the absorbance bands. Although all the complexes generated singlet oxygen ( 1 O 2 ) in aerated aqueous solutions through a photocatalytic process, IrL5 was by far the most efficient photosensitizer. Consequently, IrL5 was highly active in the photocatalytic oxidation of NADH. The formation of aggregates in DMSO at a high concentration (25 mM) was confirmed using different techniques, but was proved to be negligible in the concentration range of biological experiments. Moreover, ICP-MS studies proved that the cellular uptake of IrL2 and IrL3 is much better relative to that of IrL1 , IrL4 and IrL5 . The antiproliferative activity of IrL1–IrL5 was investigated in the dark and under blue light irradiation against different cancer cell lines. Complexes IrL1–IrL4 were found to be cytotoxic under dark conditions, while IrL5 turned out to be weakly cytotoxic. Despite the low cellular uptake of IrL5 , this derivative exhibited a high increase of cytotoxicity upon blue light irradiation resulting in photocytotoxicity indexes (PI) up to 38. IrL1–IrL4 showed lower photocytotoxicity indexes ranging from 1.3 to 17.0. Haemolytic experiments corroborated the compatibility of our complexes with red blood cells. Confocal microscopy studies proved their accumulation in mitochondria, leading to mitochondrial membrane depolarization, and ruled out their localization in lysosomes. Overall, the mitochondria-targeted activity of IrL5 , which inhibits considerably the viability of cancer cells upon blue light irradiation, allows us to outline this PS as a new alternative to traditional chemotherapeutic agents.

In-vitro and In-vivo Photocatalytic Cancer Therapy with Biocompatible Iridium(III) Photocatalysts

Highly Efficient Ir(III)-Coumarin Photo-Redox Catalyst for Synergetic Multi-Mode Cancer Photo-Therapy

Single‐Cell Quantification of a Highly Biocompatible Dinuclear Iridium(III) Complex for Photocatalytic Cancer Therapy

Axisymmetric Bis-Tridentate Ir(iii) Photoredox Catalysts for Anticancer Phototherapy under Hypoxia

Biotin-modified Cyclometalated Iridium-Based Photosensitizers As Mitochondria-Targeted Theranostic Agents for Tumor Photodynamic Therapy in Vitro and in Vivo

Photocatalytic glucose-appended bio-compatible Ir(III) anticancer complexes

A Cyclometallated Iridium(iii) Complex with Multi-Photon Absorption Properties As an Imaging-Guided Photosensitizer.

Anticancer activity and mechanism studies of photoactivated iridium(III) complexes toward lung cancer A549 cells

Rational design of iridium-porphyrin conjugates for novel synergistic photodynamic and photothermal therapy anticancer agents

Synthesis, Photophysical and Anticancer Properties of Mitochondria-Targeted Phosphorescent Cyclometalated Iridium(iii) N-heterocyclic Carbene Complexes.

Synthesis of Iridium-Based Nanocomposite with Catalase Activity for Cancer Phototherapy

Biotin-Functionalized Iridium-Based Nanoparticles As Tumor Targeted Photosensitizers for Enhanced Oxidative Damage in Tumor Photodynamic Therapy

Anticancer effect evaluation in vitro and in vivo of iridium(III) polypyridyl complexes targeting DNA and mitochondria

Dual Functions of Cyclometalated Iridium(III) Complexes: Anti-Metastasis and Lysosome-Damaged Photodynamic Therapy.

Cyclometalated Ir(III) Complexes as Mitochondria-Targeted Photodynamic Anticancer Agents

AIE-active Iridium(iii) Complex Integrated with Upconversion Nanoparticles for NIR-irradiated Photodynamic Therapy.

A Pair of Deep Red Phosphorescent Responsive Emissive Cyclometalated Iridium (III) Complexes as Carbonic Anhydrase Inhibitor and Effective Theranostic Photosensitizer

Mixed-ligand iridium(iii) complexes as photodynamic anticancer agents.

Towards efficient Ir(iii) anticancer photodynamic therapy agents by extending π-conjugation on N^N ligands

Iridium nanozyme-me diate d photoacoustic imaging-guide d NIR-II photothermal therapy and tumor microenvironment regulation for targeted eradication of cancer stem cells

Synthesis, Characterization and Biological Evaluation of Two Cyclometalated Iridium(iii) Complexes Containing a Glutathione S-transferase Inhibitor.